La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Magnasense Gestione

Gestione criteri di controllo 0/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Marco Wititteveen

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	1.3yrs
Proprietà del CEO	n/a
Durata media del management	1.3yrs
Durata media del Consiglio di amministrazione	2.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Marco Wititteveen

1.3yrs

Mandato

Mr. Marco Wititteveen serves as Chief Executive Officer of Magnasense AB (formerly known as AegirBio AB (publ)) since June 15, 2023. He has previously had multiple different roles in Med Tech and diagnosti...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Bradley Messmer	Chief Scientific Officer & Member of the Board	no data	SEK 1.28m	1.39% SEK 150.2k
Marco Wititteveen	Chief Executive Officer	1.3yrs	Nessun dato	Nessun dato
Niklas Andersson	Chief Financial Officer	1.7yrs	Nessun dato	Nessun dato
Vasiliki Fragkou	Chief Operating Officer	less than a year	Nessun dato	Nessun dato

1.3yrs

Durata media

Gestione esperta: Il team dirigenziale di MAGNA non è considerato esperto (durata media 1.2 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Bradley Messmer	Chief Scientific Officer & Member of the Board	4.6yrs	SEK 1.28m	1.39% SEK 150.2k
Seppo Makinen	Independent Member of the Board	4.6yrs	SEK 168.00k	Nessun dato
William Vickery	Independent Director	2.7yrs	Nessun dato	Nessun dato
Iain L. Chapple	Member of Scientific Advisory Board	less than a year	Nessun dato	Nessun dato
Sofia Bertling	Independent Director	2.7yrs	Nessun dato	Nessun dato
Fredrik Haglund	Independent Member of the Board	4.3yrs	SEK 48.00k	0.52% SEK 56.2k
Adam Cheifetz	Scientific Advisory Board	less than a year	Nessun dato	Nessun dato
Melissa Grant	Member of Scientific Advisory Board	less than a year	Nessun dato	Nessun dato

2.7yrs

Durata media

54yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di MAGNA non è considerato esperto (durata media del mandato 2.6 anni), il che suggerisce un nuovo consiglio.

Magnasense Gestione

Gestione criteri di controllo 0/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Magnasense AB Announces Chief Financial Officer Changes

AegirBio AB Appoints Melissa Grant to its Scientific Advisory Board

AegirBio AB (publ), Annual General Meeting, Jun 28, 2024

AegirBio AB (publ), Annual General Meeting, Jun 28, 2024

AegirBio AB (publ) Announces Intention of Anders Ingvarsson to Resign as Board Member and Chairman

AegirBio AB (Publ) Announces the Appointment of Iain L. C. Chapple to the Scientific Advisory Board

Recent updates

First half 2024 earnings released: kr0.42 loss per share (vs kr1.36 loss in 1H 2023)

Magnasense AB Announces Chief Financial Officer Changes

AegirBio AB Appoints Melissa Grant to its Scientific Advisory Board

AegirBio AB (publ), Annual General Meeting, Jun 28, 2024

AegirBio AB (publ), Annual General Meeting, Jun 28, 2024

First quarter 2024 earnings released: kr0.16 loss per share (vs kr0.64 loss in 1Q 2023)

New minor risk - Share price stability

AegirBio AB (publ) Announces Intention of Anders Ingvarsson to Resign as Board Member and Chairman

New major risk - Negative shareholders equity

Full year 2023 earnings released: kr2.38 loss per share (vs kr18.90 loss in FY 2022)

AegirBio AB (Publ) Announces the Appointment of Iain L. C. Chapple to the Scientific Advisory Board

New minor risk - Share price stability

AegirBio AB (publ) Appoints Adam S. Cheifetz as Scientific Advisory Board

Aegirbio AB Receives Phase 1 Award from the National Institutes of Health (Nih) Rapid Acceleration of Diagnostics (Radx®) Tech Program for an Accessibility Project for Multiplex Testing

AegirBio Announces Management Changes

Aegirbio AB (Publ) Announces CEO Changes

Independent Member of the Board exercised options to buy kr86k worth of stock.

AegirBio AB (publ) announced that it expects to receive SEK 55 million in funding from Atlas Special Opportunities LLC

High number of new and inexperienced directors

AegirBio Receives Approval from the Notified Body to Prolong the Shelf Life of Its Covid-19 Antigen Test

AegirBio Announces First Clinical Saliva TDM Study in US

High number of new and inexperienced directors

High number of new and inexperienced directors

AegirBio AB (publ) Receives Intention to Grant from the European Patent Office

New 90-day high: kr30.88

Aegirbio Announces the Addition of Brandon Steele to Their Senior Management Team as Chief Commercial Officer

AegirBio AB (publ) (OM:AEGIR) agreed to acquire LifeAssays AB (publ) (NGM:LIFE B)

New 90-day high: kr25.50

AegirBio AB (publ) Announces That the Direct Aid of Approximately SEK 4.3 Million or €419,500 Granted to Aegirbio AB’s Eurostar application

Aegirbio Commences FDA Fast Track Process with COVID-19 Test

Aegirbio Announces Convincing Results for Aegirbio's Coronavirus Test in Italian-Swedish Study

Aegirbio AB Signs A Research & Development Agreement with MediaPharma

AegirBio AB (publ) (OM:AEGIR) acquired Viraspec AB for SEK 10 million.

AMMINISTRATORE DELEGATO

Mandato

Gruppo dirigente

Durata media

Membri del Consiglio di amministrazione

Durata media

Età media